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Purpose.To examine theusefulnessofcardiovascular riskestimationmodelsinpeople with diabetes. Methods.Review ofpublished
studies that compare the discriminative power of major cardiovascular risk factors single or in combination in individuals with
and without diabetes, for major cardiovascular outcomes. Results. In individuals with and without diabetes, major risk factors
aﬀect cardiovascular risk similarly, with no evidence of any signiﬁcant interaction. Accounting for diabetes-speciﬁc parameters,
cardiopreventative therapies can signiﬁcantly improve risk estimation in diabetes. General and diabetes-speciﬁc cardiovascular
risk models have a useful discriminative power, but tend to overestimate risk in individuals with diabetes. Their impact on care
delivery, adherence to therapies, and patients’ outcome remain poorly understood. Conclusions. The high-risk status conferred by
diabetes does not preclude the estimation of absolute cardiovascular risk estimation using global risk tools in individuals with
diabetes, as this is useful for the initiation and intensiﬁcation of preventive measures.
1.Introduction
The incidence of cardiovascular disease (CVD) risk factors
is higher in diabetic patients than in nondiabetic individuals
[1]. Therefore, estimating global absolute cardiovascular risk
in this population is essential for better risk factor man-
agement.
Decision making and patient education in modern
medicine increasingly relies on risk estimation models. A
risk model is a mathematical equation that can be used to
estimate the probability of having prevalent disease, incident
disease,orapooroutcomeamongdiseasedindividuals[2,3].
The use of prediction models in cardiovascular medicine has
become popular during the last three decades, largely driven
by the Framingham study. This cohort study allowed the
development of a several cardiovascular disease risk models
[4–6], which have been reformulated, simpliﬁed through
scores (obtained by the assignment of points to each risk
factor included into the model) or charts, recalibrated to
other populations, or replaced by similar models in other
settings or contexts. The risk models generally estimate the
probability of future events within a given time period
(usually over a 5- or 10-year time horizon) in individuals
with no prior cardiovascular event. This estimate depends
on the combination and levels of all risk factors rather than
on the presence of any single risk factor. The risk estimates
are used to guide primary prevention. Modern guidelines
increasingly emphasize the importance of estimating the
individual’s global cardiovascular risk as a more appropriate
basis for risk factor management.
Three diﬀerent approaches have been used to account for
exposure to chronic hyperglycemia in CVD risk estimation.
The ﬁrst approach includes diabetes status in the risk tool
such that, all things being equal, a diabetic patient will
always have a higher risk than a nondiabetic patient with
a similar risk factor proﬁle such as blood pressure. The
second approach builds separate models for individuals with
and without diabetes. In this approach, the knowledge of2 ISRN Cardiology
risk factor eﬀect in the diabetic population does not inform
CVD risk estimation in the nondiabetic population. Finally,
the third approach classiﬁes individuals with diabetes as
having a risk level equivalent to that of individuals without
diabetes who survived a cardiovascular event, making them
eligible for preventive therapies without further CVD risk
estimation. However, this does not account for the fact that
CVD risk is not uniformly distributed, but follows a gradient
from the lowest to the highest risk [7].
In this paper, we examine the utility of existing CVD risk
estimation models (also referred to as absolute risk equa-
tions) in individuals with diabetes. We attempt to answer
three key questions. (1) How does CVD risk factor proﬁle
diﬀer among individuals with diabetes and nondiabetic
individuals? (2) Whatare theopportunities forreﬁning CVD
risk estimation aﬀorded by the chronic dysglycemic envi-
ronment? (3) Does the performance of CVD risk estimation
tools developed speciﬁcally for individuals with diabetes
diﬀer from tools developed for the general population?
2 .C V DR i s kF a c t o rP r o ﬁ l ea m o n gI n d i v i d u a l s
withDiabetesandNondiabeticIndividuals
2.1. Blood Pressure and CVD Risk among Individuals with
Diabetes and Those without Diabetes. Blood pressure (BP)
is a major determinant of cardiovascular risk. Compared to
individuals without diabetes, average BP levels in individuals
with diabetes are generally higher. Consequently, a catego-
rization of the population based on arbitrary BP cutoﬀ levels
will amount to a higher prevalence of hypertension among
individuals with diabetes than in the rest of the population
[8–10]. On this basis, it has generally been known that
there is a higher cardiovascular risk related to BP among
individuals with diabetes than nondiabetic individuals. Such
an approach is simplistic, especially given the continuous
association between BP and CVD risk without evidence of
a threshold below which the risk is stable or null. At each
BP level, both the absolute and relative CVD risk levels may
be higher among individuals with diabetes. Therefore, a key
question is whether any change in BP level confers the same
level of relative risk among individuals with diabetes and
thosewithoutdiabetes.Inotherwords,isthereaninteraction
between diabetes and BP to aﬀect CVD risk?
This question has been examined in many studies over
the last four decades. At least three studies concluded an
interaction, with a higher risk among individuals with
diabetes in one study [11] or in those without diabetes in
two studies [12, 13]. A much larger, better-designed, and
well-conductedstudy,theAPCSCmeta-analysis,didnotﬁnd
an interaction between diabetes and blood pressure [14]. In
this study, the association between systolic BP and the risk of
multiplecardiovasculareventswaslinearandcontinuous(on
the log scale) in individuals with and without diabetes [14].
Each10mmHgincreaseinSBPwasassociatedwiththesame
relative risk of cardiovascular event among individuals with
diabetes and those without diabetes [14].
2.2. Lipid Levels and Risk of Cardiovascular Diseases among
Individuals with Diabetes and Those without Diabetes. It is
generally known that the “diabetes dyslipidemia” is typically
c h a r a c t e r i z e db yh i g hl e v e l so ft r i g l y c e r i d e s ,l o wl e v e l so f
HDL cholesterol, and normal or near-normal levels of
LDL cholesterol [15]. This description has fueled a debate
around two main questions. (1) Which lipid variable is most
correlated with CVD risk among individuals with diabetes?
(2) Do all lipid variables confer the same level of CVD risk in
individuals with diabetes and those without the condition?
We will focus on the second question. A few studies
have directly compared the relative eﬀect of various lipid
variables on CVD risk among individuals with diabetes
and those without diabetes. Regarding total and LDL
cholesterol, the Multiple Risk Factors Intervention Trial
(MRFIT) suggested that total cholesterol is associated with
a lower relative CVD risk among individuals with diabetes
compared to those with the disease [13]. However, the vast
majority of studies, including the APCSC study, found no
interaction between diabetes, total and HDL cholesterol, and
CVD risk [14]. As previously observed, the APCSC study
showed that triglycerides, HDL and non-HDL-cholesterol,
and total/HDL cholesterol ratio inﬂuence CVD risk similarly
among individuals with diabetes and those without diabetes.
2.3. Smoking and Cardiovascular Risk among Individuals with
DiabetesandThosewithoutDiabetes. Existingstudiesconcur
on the fact that prevalence of smoking among individuals
with diabetes is not appreciably diﬀerent from that in
the general population [16, 17]. One study has indicated
that smoking could account for up to 65% of cardio-
vascular deaths in people with diabetes; however, studies
that have investigated the statistical interaction between
diabetes and smoking on the risk of major cardiovas-
cular outcomes have generated conﬂicting results [1, 13,
18–22]. Nevertheless, the trends indicated an absence of
interaction eﬀect between smoking and diabetes on the
CVD risk in most studies including Framingham study [1],
the Paris Prospective study [20], and the APCSC study
[23].
3. Reﬁnement of CVD Risk Estimation among
IndividualswithDiabetes—Opportunities
andChallenges
The aforementioned ﬁndings indicating that traditional
risk factors used for CVD risk estimation aﬀect CVD risk
among individuals with diabetes and those without diabetes,
similarly, argue against a development of separate risk
models for these two groups. However, given the speciﬁc
distribution of some of risk factors in the context of diabetes,
these can contribute to an improvement or a modiﬁcation
of risk prediction among individuals with diabetes, but not
necessarilyamongthosewithoutdiabetes.Thisisparticularly
thecasefordiabetes-speciﬁc CVD risk factorsand preventive
therapies.
3.1. Cardiovascular Risk Factors Speciﬁc to Diabetes. Markers
of chronic hyperglycemia conventionally used for the diag-
nosis and control of diabetes are independent risk factors
for CVD. Indeed, fasting and postprandial glucose levels,ISRN Cardiology 3
as well as hemoglobin A1c (HbA1c) are linearly associated
with CVD risk among individuals with and without diabetes
[24, 25]. The inclusion of markers of chronic hyperglycemia
such as HbA1c used as a continuous variable in risk models
does not necessarily improve CVD risk estimation in the
nondiabetic population [26]. Inclusion of diabetes status
as a binary variable further decreases the extent of the
contribution of glycemia to CVD risk prediction among
individuals without diabetes, thus making it less useful to
CVD risk discrimination. This is not the case for those with
diabetes, among whom the contribution of these parameters
has been unequivocally demonstrated [27, 28].
Some microvascular complications of diabetes are inde-
pendent CVD risk markers and are thus informative and
contribute to prediction even in the presence of other known
risk factors. Microvascular complications that have been
used in CVD risk estimation tools include diabetic retinopa-
thy and microalbuminuria, derived from risk prediction
models employed in the ADVANCE study [27].
Studies have suggested that age and diabetes interact
to aﬀect CVD risk [29], with age having a multiplicative
eﬀect after the diagnosis of diabetes, thus justifying its
inclusion in diabetes-speciﬁc tools as two parameters: age
at diagnosis of diabetes and duration of diabetes [29]. This
consideration has largely inﬂuenced the development of the
United Kingdom Prospective Diabetes Study (UKPDS) risk
scores [29, 30], that has been used in more recent models
[27, 31, 32].
3.2. Preventive Cardiovascular Therapies. Contemporary
management algorithms assume that patients in general and
especially individuals with diabetes are naive of preventive
treatment,atleastuntilthediagnosisofdiabetes.However,in
practice,thevastmajorityofindividualswithdiabetesreceive
at least one cardiopreventive medication, generally blood
pressure or lipid-lowering medications, or aspirin [33].
These medications are used less frequently in the general
population. Given that medications modify the expression of
risk factors, they should be accounted for in the estimation
of global CVD risk. Very few models have actually accounted
for the eﬀect of treatment [34]. Some risk models have
attempted to do this by including blood pressure treatment
in CVD risk models [6]. This approach however is not
optimal, as it does not account for the fact that medications
are more likely to be prescribed to individuals with diabetes
than those without diabetes. Hence, the eﬀect of treatment
for high blood pressure in a mixed population (individuals
with and without diabetes) will be diluted by the lower
levels of prescription among those without diabetes. This
indicates the need for more appropriate models of CVD
risk estimation among individuals with diabetes, especially
among those already receiving several preventative therapies.
4. Performance of CardiovascularRisk
EstimationToolsamong
Individualswith Diabetes
The number of CVD risk models developed in the general
population or among individuals with diabetes has been
increasing. A systematic review of these tools is beyond the
scope of this paper [27, 28]. However, the vast majority of
available models was developed in predominantly nondia-
beticpopulationsandhashardlybeenvalidatedinexclusively
diabetic populations.
Generally, risk models have been developed using logistic
regressions or survival analyses. The coeﬃcients of diﬀerent
factors included in the ﬁnal equation indicate their relative
contribution to the overall CVD risk [2]. The validation of
a model consist of testing whether the risk tool correctly
estimates the probability of future events in one or several
populations other than the one in which it was developed.
The two characteristics that are generally evaluated are
discrimination and calibration [2]. Discrimination is the
ability to correctly classify individuals who go on to develop
a cardiovascular event and those who remain event free
[2]. For example, if there are two individuals with diabetes,
with one developing a cardiovascular event after certain time
and the other remaining CVD free, a model with a high
discriminative ability will systematically assign a higher risk
to the ﬁrst subject compared to the second. Calibration is
the extent to which predicted risk from a model matches
observed risk in the population [2]. For instance, a 5-year
estimated probability of cardiovascular disease of 20% for a
patient means that, in a given group of patients with similar
characteristics, 20% will experience a cardiovascular event
within a 5-year period.
Framingham CVD risk equations for the general popula-
tion [33, 35–38] and diabetes-speciﬁc CVD risk tools such
as those derived from the UKPDS study [33, 37–39]h a v e
been tested independently among individuals with diabetes.
These models generally include age or its component, sex,
blood-pressure-relatedvariables,levelsofvariousbloodlipid
variables, and smoking. Available studies suggest that the
discriminative power of these CVD risk equations among
individuals with diabetes varies for low to acceptable for
CVD risk estimation. Recent studies have also indicated a
tendency toward systematic overestimation of CVD risk by
the two groups (Framingham and UKPDS) of equations
among individuals with diabetes [27, 33]. Some of the
studies that compared these equations did not ﬁnd a major
diﬀerence [37, 40–42]; others found a better estimation
with the used of the UKPDS tools [33, 38]. These studies
have shown that the absolute CVD risk is not uniformly
distributed among individuals with diabetes [7]. It follows
a gradient from low to high risk, thus adequately capturing
this gradient in risk estimation may allow improvement of
therapy and intensiﬁcation of prevention among individuals
with diabetes [7].
5. Effect of the Use of CVD Risk Tools on
Providerand Patient Behaviors
Whether the adoption of CVD risk models is accompanied
by changes in healthcare provider and patient behaviors
and thus a better adherence with preventive cardiovascular
measures has not been extensively explored. To our knowl-
edge, no study has addressed this question exclusively among4 ISRN Cardiology
individuals with diabetes. In the US-based Atherosclerosis
Assessment Via Total Risk trial (AVIATOR) [43], which
included 368 participants from the general population,
free of prior CVD and not on statin therapy, who were
randomly assigned to intervention and control arms. In
the intervention group, the 10-year absolute CVD risk
was computed using the Framingham equation. The risk
estimationwasthentranslatedinsimpletermsandappended
to the medical ﬁle of each patient. In the control group,
preventive measures indicated in the existing guidelines were
appended to the medical ﬁle of patients. During followup,
the level of statin prescription was similar among high-risk
patients (10-year risk > 20%) in both groups. However,
in the control group, more participants with moderate
risk (10–19%)—and thus eligible for statin prescription
according to existing guidelines—received statins compared
to the corresponding intervention arm. Among the low-
risk group (<10%), there was a signiﬁcant higher level of
statin prescription in the intervention group. Physicians
in the intervention group tended to recommend smoking
cessation and those in the control group to recommend
dietary changes [43]. More recently, a UK-based study
examinedtheeﬀectofCVDriskcommunicationonpatients’
health-related behaviors. This randomized trial allocated
194 adults (with and without diabetes) with a CVD risk
≥20%totwogroups,onereceivingpersonalizedinformation
on their level of risk and the other no information on
their risk level. There was a slight, although nonsignif-
icant, increase in objectively measured physical activity
levels (using accelerometers) over a one-month period [44].
These results indicate the need to rethink risk commu-
nication strategies to patients in order to inﬂuence their
behaviors.
6. Conclusions
CVD remains the leading cause of disability and death
amongindividualswithdiabetes.Itisthereforeimportantfor
individuals with diabetes to have access to more precise and
useful information on their CVD risk level, in order to mod-
ify their health-related behaviors. Healthcare providers also
needinstrumentsthatwillhelpineducatingdiabeticpatients
on their risk of major events (e.g., myocardial infarction and
stroke) and to initiate appropriate preventive interventions
(pharmacological and nonpharmacological). Compared to
nondiabetic subjects, individuals with diabetes generally
have a higher CVD risk and deserve due attention. However,
theCVD risk is not uniformlydistributed in individuals with
diabetes, but rather follows a gradient [7]. Adequately cap-
turing this gradient does not only depend on individual risk
factors but on their combination, thus the need for an esti-
mation of global CVD risk among individuals with diabetes
[45]. Thus, the use of CVD risk estimation tools is probably
beneﬁcial for the prevention of cardiovascular events in
patients with diabetes, especially as the performance of these
tools has generally improved over time, and the inclusion
of diabetes-speciﬁc risk factors has helped to reﬁned risk
estimation.
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